Glaukos Corp (GKOS):企業の製品パイプライン分析2018

◆英語タイトル:Glaukos Corp (GKOS) - Product Pipeline Analysis, 2018 Update
◆商品コード:DATA904C2867
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD1,500 ⇒換算¥222,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD2,250 ⇒換算¥333,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Glaukos Corp (Glaukos) is an ophthalmic medical device company that research and develops micro technologies to improve glaucoma therapy. The company develops injectable micro-scale therapies to address the complete range of glaucoma disease states and progression. It provides products such as microstent devices to treat glaucoma such as iStent trabecular micro-bypass stent for the treatment of mild- tomoderate open-angle glaucoma. Glaukos’ iStent is used in conjunction with cataract surgery. Glauko’s iStent improves outflow by creating a patent bypass between the anterior chamber and Schlemm’s canal. The company markets its products through a network of distributors in Germany, Italy, Canada, Portugal, Spain, the UK and France, among others. Glaukos is headquartered in San Clemente, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Glaukos Corp
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Glaukos Corp Company Overview 6
Glaukos Corp Company Snapshot 6
Glaukos Corp Pipeline Products and Ongoing Clinical Trials Overview 6
Glaukos Corp – Pipeline Analysis Overview 8
Glaukos Corp – Key Facts 8
Glaukos Corp – Major Products and Services 9
Glaukos Corp Pipeline Products by Development Stage 10
Glaukos Corp Ongoing Clinical Trials by Trial Status 12
Glaukos Corp Pipeline Products Overview 15
GTS400 15
GTS400 Product Overview 15
iDose Travoprost Intraocular Implant 16
iDose Travoprost Intraocular Implant Product Overview 16
iDose Travoprost Intraocular Implant Clinical Trial 17
IOP Sensor System 18
IOP Sensor System Product Overview 18
iStent Infinite 19
iStent Infinite Product Overview 19
iStent Infinite Clinical Trial 20
iStent inject Trabecular Micro-Bypass Stent 21
iStent inject Trabecular Micro-Bypass Stent Product Overview 21
iStent inject Trabecular Micro-Bypass Stent Clinical Trial 22
iStent SA 25
iStent SA Product Overview 25
iStent SA Clinical Trial 26
iStent Supra Suprachoroidal Micro-Bypass Stent 30
iStent Supra Suprachoroidal Micro-Bypass Stent Product Overview 30
iStent Supra Suprachoroidal Micro-Bypass Stent Clinical Trial 31
Glaukos Corp – Key Competitors 34
Glaukos Corp – Key Employees 35
Glaukos Corp – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Glaukos Corp, Recent Developments 37
Jun 25, 2018: Glaukos’ iStent inject micro-bypass device gets FDA approval 37
May 09, 2018: Glaukos Announces First Quarter 2018 Financial Results 37
Apr 14, 2018: IDE Pivotal Trial Results for Glaukos iStent inject Show Significant Reductions in Unmedicated IOP in Glaucoma Subjects Undergoing Cataract Surgery 38
Apr 11, 2018: Multiple Surgeon Presentations to Include Glaukos Technologies at 2018 American Society of Cataract and Refractive Surgery 39
Feb 28, 2018: Glaukos Reports Fourth Quarter and Full Year 2017 Financial Results 41
Feb 28, 2018: Raysearch Laboratories: First clinic now live with RayCare 42
Feb 27, 2018: Glaukos Technologies Featured in Numerous Presentations at 2018 American Glaucoma Society Meeting 43
Feb 27, 2018: International Study Shows Long-Term Titrated IOP Control with 1, 2 or 3 Glaukos iStent Trabecular Micro-Bypass Stents in Open-Angle Glaucoma Patients 44
Feb 26, 2018: Apollo Endosurgery Announces First ORBERA U.S. Post-Approval Publication 45
Feb 08, 2018: Glaukos iStent Trabecular Micro-Bypass Stent Reduced IOP and Lowered Medication Burden in Patients with Severe Glaucoma, According to New Study 46
Appendix 48
Methodology 48
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Glaukos Corp Pipeline Products and Ongoing Clinical Trials Overview 6
Glaukos Corp Pipeline Products by Equipment Type 7
Glaukos Corp Pipeline Products by Indication 7
Glaukos Corp Ongoing Clinical Trials by Trial Status 7
Glaukos Corp, Key Facts 8
Glaukos Corp, Major Products and Services 9
Glaukos Corp Number of Pipeline Products by Development Stage 10
Glaukos Corp Pipeline Products Summary by Development Stage 11
Glaukos Corp Ongoing Clinical Trials by Trial Status 12
Glaukos Corp Ongoing Clinical Trials Summary 13
GTS400 - Product Status 15
GTS400 - Product Description 15
iDose Travoprost Intraocular Implant - Product Status 16
iDose Travoprost Intraocular Implant - Product Description 16
iDose Travoprost Intraocular Implant - A Prospective, Randomized, Phase III IND Study of iDose Travoprost in Open-angle Glaucoma Patients 17
iDose Travoprost Intraocular Implant - Assessment of iDose Delivery System's Safety and Preliminary Efficacy for the Reduction of Elevated Intraocular Pressure 17
IOP Sensor System - Product Status 18
IOP Sensor System - Product Description 18
iStent Infinite - Product Status 19
iStent Infinite - Product Description 19
iStent Infinite - A Prospective, Multi-center, Single-arm Clinical Study to Evaluate the Safety and Efficacy of iStent Infinite in Refractory Glaucoma Patients 20
iStent inject Trabecular Micro-Bypass Stent - Product Status 21
iStent inject Trabecular Micro-Bypass Stent - Product Description 21
iStent inject Trabecular Micro-Bypass Stent - A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects Treated with Two Second Generation Micro-bypass Stents and One Suprachoroidal Stent 22
iStent inject Trabecular Micro-Bypass Stent - A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects with Cataract Treated with Cataract Surgery Plus One Trabecular Micro-bypass Stent and One Suprachoroidal Stent 22
iStent inject Trabecular Micro-Bypass Stent - A Prospective Evaluation of the Second Generation iStent Inject in Open-angle Glaucoma Subjects on Two Preoperative Topical Ocular Hypotensive Medications 23
iStent inject Trabecular Micro-Bypass Stent - A Prospective, Randomized Evaluation of Subjects with Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naive to Medical and Surgical Therapy, Treated with Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost Ophthalmic Solution 0.004% 23
iStent inject Trabecular Micro-Bypass Stent - A Prospective, Randomized, Single-masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos Trabecular Micro-bypass Stent Model GTS400 Using the G2-M-IS Injector System in Conjunction with Cataract Surgery 24
iStent inject Trabecular Micro-Bypass Stent - A Randomized Controlled Trial of Cataract Surgery Versus Combined Cataract Surgery with Insertion of iStent Inject 24
iStent SA - Product Status 25
iStent SA - Product Description 25
iStent SA - A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects Treated with Second Generationtrabecular Micro-bypass Stents and One Suprachoroidal Stent a Multicenter Study According to Mpg §23.B 26
iStent SA - A Prospective Evaluation of Open-angle Glaucoma Subjects on One Topical Hypotensive Medication (Prostaglandin) Treated with Two Trabecular Micro-bypass Stents (iStent Inject) 26
iStent SA - A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medications (One a Prostaglandin) Treated with Two Trabecular Micro-bypass Stents (iStent Inject) and a Postoperative Topical Prostaglandin 27
iStent SA - Initial Phase of U.S. IDE Clinical Trial for Standalone Version of iStent inject 27
iStent SA - The Effect of Glaucoma Surgery on Aqueous Dynamics in Patients with Glaucoma or Ocular Hypertension: An Observational Study 28
iStent SA - Trabeculectomy with MMC and I Stent in Uveitic Glaucoma and POAG : Outcomes and Prognostic Factors 28
iStent SA - US Investigational Device Exemption (IDE) Pivotal Study of iStent SA Standalone Micro-Invasive Glaucoma Surgery 29
iStent Supra Suprachoroidal Micro-Bypass Stent - Product Status 30
iStent Supra Suprachoroidal Micro-Bypass Stent - Product Description 30
iStent Supra Suprachoroidal Micro-Bypass Stent - A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects Treated with Second Generationtrabecular Micro-bypass Stents and One Suprachoroidal Stent a Multicenter Study According to Mpg §23.B 31
iStent Supra Suprachoroidal Micro-Bypass Stent - A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects Treated with Two Second Generation Micro-bypass Stents and One Suprachoroidal Stent 31
iStent Supra Suprachoroidal Micro-Bypass Stent - A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects with Cataract Treated with Cataract Surgery Plus One Trabecular Micro-bypass Stent and One Suprachoroidal Stent 32
iStent Supra Suprachoroidal Micro-Bypass Stent - A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With One Suprachoroidal Stent 32
iStent Supra Suprachoroidal Micro-Bypass Stent - A Prospective Evaluation of Open-angle Glaucoma Subjects with One Prior Trabeculectomy Treated Concurrently with One Suprachoroidal Stent and Two Trabecular Micro-bypass Stents and a Postoperative Prostaglandin 33
iStent Supra Suprachoroidal Micro-Bypass Stent - A Prospective, Randomized, Single-masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos Suprachoroidal Stent Model G3 in Conjunction with Cataract Surgery 33
Glaukos Corp, Key Employees 35
Glaukos Corp, Subsidiaries 36
Glossary 50

List of Figures
Glaukos Corp Pipeline Products by Equipment Type 7
Glaukos Corp Pipeline Products by Development Stage 10
Glaukos Corp Ongoing Clinical Trials by Trial Status 12

★海外企業調査レポート[Glaukos Corp (GKOS):企業の製品パイプライン分析2018]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Advantor Systems Corporation:企業の戦略・SWOT・財務情報
    Advantor Systems Corporation - Strategy, SWOT and Corporate Finance Report Summary Advantor Systems Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Impala Platinum Holdings Ltd:企業の戦略・SWOT・財務情報
    Impala Platinum Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Impala Platinum Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • BM-Bank Public Joint Stock Company:企業のM&A・事業提携・投資動向
    BM-Bank Public Joint Stock Company - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BM-Bank Public Joint Stock Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on m …
  • Acorda Therapeutics Inc (ACOR)-製薬・医療分野:企業M&A・提携分析
    Summary Acorda Therapeutics Inc (Acorda) is a biopharmaceutical company that discovers, develops, and commercializes therapies for treating patients with neurological disorders. The company’s commercial products include Ampyra (dalfampridine), a treatment to improve walking in patients with multiple …
  • Merrimack Pharmaceuticals Inc (MACK):医療機器:M&Aディール及び事業提携情報
    Summary Merrimack Pharmaceuticals Inc (Merrimack) is a clinical stage biopharmaceutical company that develops and commercializes medicines for the treatment of various types of cancers. The company’s marketed portfolio consists of Onivyde (irinotecan liposome injection) that encases irinotecan (mark …
  • University of Leeds:製薬・医療:M&Aディール及び事業提携情報
    Summary University of Leeds (University of Leeds) is an educational university that offers academic programs. The university offers undergraduate, post graduate, research degrees, online and distance learning educational programs. It offers education programs in the areas of arts, biological science …
  • Tabuk Pharmaceuticals Manufacturing Company:製薬・医療:M&Aディール及び事業提携情報
    Summary Tabuk Pharmaceuticals Manufacturing Company (Tabuk), a subsidiary of Astra Industrial Group, is a drug company that develops, manufactures and markets branded generic pharmaceuticals and under-licensed products. The company offers products in various therapeutic areas including alimentary tr …
  • Ubisoft Entertainment S.A.:企業の戦略・SWOT・財務情報
    Ubisoft Entertainment S.A. - Strategy, SWOT and Corporate Finance Report Summary Ubisoft Entertainment S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Ibersol S.G.P.S., S.A.:企業の戦略・SWOT・財務分析
    Ibersol S.G.P.S., S.A. - Strategy, SWOT and Corporate Finance Report Summary Ibersol S.G.P.S., S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Schouw & Co. A/S:企業の戦略・SWOT・財務情報
    Schouw & Co. A/S - Strategy, SWOT and Corporate Finance Report Summary Schouw & Co. A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Laing O’Rourke Plc:企業の戦略的SWOT分析
    Laing O'Rourke Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • DiGi.Com Berhad (DIGI):企業の財務・戦略的SWOT分析
    DiGi.Com Berhad (DIGI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • MMRGlobal Inc (MMRF)-医療機器分野:企業M&A・提携分析
    Summary MMRGlobal Inc (MMRGlobal), formerly MMR Information Systems, Inc., is a personal health records company, which provides Personal Health Record (PHR) products and electronic safe deposit box storage solutions. It offers a wide range of secure, online products that helps consumers and professi …
  • Pantheon Resources plc (PANR):企業の財務・戦略的SWOT分析
    Summary Pantheon Resources Plc (Pantheon Resources) is an oil and gas exploration and production company. It explores, develops and produces crude oil and natural gas resource properties. The company invests in oil and gas exploration and development. It operates hydrocarbon producing basins onshore …
  • Dermira Inc (DERM):医療機器:M&Aディール及び事業提携情報
    Summary Dermira Inc (Dermira) is a biopharmaceutical company that identifies, develops and commercializes therapeutic solutions for the treatment of dermatologic diseases, such as hyperhidrosis, acne vulgaris and atopic dermatitis. The company’s product includes QBREXZA (glycopyrronium) cloth, an an …
  • DEKRA e.V.:企業の戦略的SWOT分析
    DEKRA e.V. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Parenteral Drug India Ltd (PDPL):企業の財務・戦略的SWOT分析
    Summary Parenteral Drug India Ltd (PDIL) is a healthcare company that manufactures pharmaceutical products. The company provides products such as solid and liquid orals, IV fluids, oncology products and anaesthesia products. It offers IV fluids such as carbohyrated and electrolytes; diuretics, dialy …
  • Lonza Group Ltd (LONN)-製薬・医療分野:企業M&A・提携分析
    Summary Lonza Group Ltd (Lonza) is a biopharmaceutical company that manufactures and develops chemical and biological active pharmaceutical ingredients, and other products and services. The company offers active pharmaceutical ingredients, stem cell therapies, drinking water sanitizers, vitamin B co …
  • Alcon Laboratories Inc:企業の戦略的SWOT分析
    Alcon Laboratories Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • KDDI Corporation:戦略・SWOT・企業財務分析
    KDDI Corporation - Strategy, SWOT and Corporate Finance Report Summary KDDI Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆